Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Biotest

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: -

Established: 1946-01-01

Employees: -

Market Cap: $1.4B

Website: http://www.biotest.de

Clinical Trials

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

Phase 3

Recruiting

Conditions: Community-acquired Pneumonia

Interventions: Drug: Trimodulin
Drug: Placebo (human albumin 1%)

First Posted Date: 2023-02-10

Last Posted Date: 2025-05-07

Lead Sponsor: Biotest

Target Recruit Count: 590

Registration Number: NCT05722938

Locations: 🇺🇸
Pulmonary Associates of Mobile, P.C., Mobile, Alabama, United States
🇺🇸
University of California San Francisco-Fresno, Fresno, California, United States
🇺🇸
UC Davis Health, Sacramento, California, United States

and more 131 locations

Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia

Phase 3

Terminated

Conditions: COVID-19
Pneumonia
Community-acquired Pneumonia
Bacterial Pneumonia
Respiratory Infection
Viral Pneumonia
Fungal Pneumonia
Acute Respiratory Distress Syndrome

Interventions: Drug: Placebo (human albumin 1%)
Drug: Trimodulin

First Posted Date: 2022-09-07

Last Posted Date: 2025-06-08

Lead Sponsor: Biotest

Target Recruit Count: 107

Registration Number: NCT05531149

Locations: 🇦🇷
Investigational Site #5401, Buenos Aires, Argentina
🇦🇷
Investigational Site #5403, Cordoba, Argentina
🇦🇷
Investigational Site #5402, Córdoba, Argentina

and more 61 locations

Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)

Phase 3

Terminated

Conditions: Congenital Cytomegalovirus Infection

Interventions: Drug: BT097

First Posted Date: 2021-12-27

Last Posted Date: 2025-03-10

Lead Sponsor: Biotest

Target Recruit Count: 48

Registration Number: NCT05170269

Locations: 🇩🇪
4906, Berlin, Germany
🇩🇪
4903, Bonn, Germany
🇩🇪
4902, Erlangen, Germany

and more 2 locations

Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19

Phase 2

Completed

Conditions: Covid19

Interventions: Drug: Trimodulin
Other: Placebo (human albumin 1%)

First Posted Date: 2020-10-06

Last Posted Date: 2023-01-10

Lead Sponsor: Biotest

Target Recruit Count: 166

Registration Number: NCT04576728

Locations: 🇧🇷
Investigational site # 5503, Porto Alegre, Brazil
🇧🇷
Investigational site # 5502, Santo André, Brazil
🇧🇷
Investigational site # 5505, Santo André, Brazil

and more 14 locations

Adjusted Fibrinogen Replacement Strategy

Phase 3

Completed

Conditions: Bleeding Disorder
Hypofibrinogenemia; Acquired

Interventions: Biological: BT524
Biological: FFP/Cryo

First Posted Date: 2018-02-23

Last Posted Date: 2025-06-13

Lead Sponsor: Biotest

Target Recruit Count: 222

Registration Number: NCT03444324

Locations: 🇧🇪
Site 02, Jette, Belgium
🇧🇪
Site 01, Leuven, Belgium
🇨🇿
Site 54, Brno, Czechia

and more 16 locations

This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)

Phase 3

Completed

Conditions: Immune Thrombocytopenia

First Posted Date: 2016-08-09

Last Posted Date: 2019-08-14

Lead Sponsor: Biotest

Target Recruit Count: 34

Registration Number: NCT02859909

Locations: 🇧🇬
Investigational site # 3597, Pleven, Bulgaria
🇧🇬
Investigational site # 3593, Plovdiv, Bulgaria
🇧🇬
Investigational site # 3598, Sofia, Bulgaria

and more 19 locations

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

Phase 3

Completed

Conditions: Primary Immunodeficiency Disease

First Posted Date: 2016-06-23

Last Posted Date: 2023-07-20

Lead Sponsor: Biotest

Target Recruit Count: 81

Registration Number: NCT02810444

Locations: 🇺🇸
Investigational site # 0104, Birmingham, Alabama, United States
🇺🇸
Investigational site # 0116, Los Angeles, California, United States
🇺🇸
Investigational site # 0103, Centennial, Colorado, United States

and more 16 locations

Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus

First Posted Date: 2015-09-18

Last Posted Date: 2020-01-27

Lead Sponsor: Biotest

Target Recruit Count: 36

Registration Number: NCT02554019

Locations: 🇧🇾
Study Site 37505, Gomel, Belarus
🇧🇾
Study Site 37503, Minsk District, Belarus
🇧🇾
Study Site 37501, Minsk, Belarus

and more 11 locations

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

Phase 3

Completed

Conditions: Congenital Afibrinogenemia
Congenital Hypofibrinogenemia

Interventions: Drug: BT524 (Part I)
Drug: BT524 (Part II)

First Posted Date: 2014-02-19

Last Posted Date: 2025-07-03

Lead Sponsor: Biotest

Target Recruit Count: 67

Registration Number: NCT02065882

Locations: 🇧🇬
Site 15, Sofia, Bulgaria
🇪🇬
Site 11, Cairo, Egypt
🇩🇪
Site 16, Frankfurt, Germany

and more 3 locations

Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis

Phase 2

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tregalizumab
Drug: Placebo

First Posted Date: 2013-12-03

Last Posted Date: 2017-08-24

Lead Sponsor: Biotest

Target Recruit Count: 321

Registration Number: NCT01999192

Locations: 🇺🇦
Study Site 07, Vinnytsia, Ukraine
🇺🇦
Study Site 01, Kharkiv, Ukraine
🇺🇦
Study Site 03, Kyiv, Ukraine

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy